 MORRISVILLE, N.C., May 10, 2021 GLOBE NEWSWIRE -- Liquidia Corporation NASDAQ: LQDA announced today that on May 7, 2021, it resubmitted its New Drug Application NDA for LIQ861 for the treatment of pulmonary arterial hypertension PAH. The U.S. Food and Drug Administration FDA issued a Complete Response Letter CRL regarding the NDA in November 2020 indicating that the application was incomplete and not ready for approval in its present form. Liquidia and the FDA held a Type A meeting in January 2021 to discuss the CRL and the requirements for the NDA resubmission. 